Pulmonx Corp (LUNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulmonx Corp (LUNG) has a cash flow conversion efficiency ratio of -0.221x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.10 Million) by net assets ($45.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LUNG equity to assets ratio to measure how much of total assets are equity-financed.
Pulmonx Corp - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Pulmonx Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Pulmonx Corp's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Pulmonx Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulmonx Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Safety Shot Inc
NASDAQ:SHOT
|
-0.072x |
|
Atlantic International Corp. Common Stock
NASDAQ:ATLN
|
0.255x |
|
PW Consolidated Bhd
KLSE:7134
|
0.093x |
|
tsh biopharmoration Ltd
TWO:8432
|
0.027x |
|
JKG Land Bhd
KLSE:6769
|
0.154x |
|
Evermore Chemical Industry Co Ltd
TW:1735
|
0.061x |
|
LLORENTE + CUENCA EO -01
F:91P
|
N/A |
|
Endurance Gold Corp
V:EDG
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Pulmonx Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Pulmonx Corp from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see LUNG company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $54.12 Million | $-32.45 Million | -0.600x | -63.14% |
| 2024-12-31 | $85.81 Million | $-31.54 Million | -0.368x | -15.62% |
| 2023-12-31 | $118.31 Million | $-37.61 Million | -0.318x | -8.46% |
| 2022-12-31 | $154.01 Million | $-45.14 Million | -0.293x | -36.70% |
| 2021-12-31 | $193.24 Million | $-41.43 Million | -0.214x | -58.27% |
| 2020-12-31 | $226.13 Million | $-30.63 Million | -0.135x | -222.24% |
| 2019-12-31 | $-187.38 Million | $-20.77 Million | 0.111x | +0.81% |
| 2018-12-31 | $-167.33 Million | $-18.39 Million | 0.110x | -99.85% |
| 2017-12-31 | $-63.18K | $-4.64 Million | 73.407x | +10136.98% |
| 2016-12-31 | $-2.84 Million | $-2.03 Million | 0.717x | -25.61% |
| 2015-12-31 | $-2.65 Million | $-2.56 Million | 0.964x | +1.67% |
| 2014-12-31 | $-1.41 Million | $-1.34 Million | 0.948x | +107.46% |
| 2013-12-31 | $-1.78 Million | $-811.78K | 0.457x | -- |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more